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Sympathetic hyperactivity and parasympathetic insufﬁciency characterize blood pressure
(BP) control in genetic hypertension. This shift is difﬁcult to investigate in anesthetized
rats. Here we present a pharmacological approach to simultaneously provoke sympa-
thetic and parasympathetic transmitter release, and identify their respective roles in the
concomitant cardiovascular response.To stimulate transmitter release in anesthetized nor-
motensive (WKY) and spontaneously hypertensive rats (SHR), we injected intravenously 4-
aminopyridine (4-AP), a voltage-sensitive K+ channel (KV) inhibitor. A femoral artery catheter
monitored BP, an ascending aorta ﬂow-probe recorded cardiac output and heart rate (HR).
Total peripheral vascular resistance (TPVR) was calculated. 4-AP-induced an immediate,
atropine (muscarinic antagonist)- and hexamethonium (ganglion blocker)-sensitive bradycar-
dia inWKY, and in both strains, a subsequent, sustained tachycardia, and norepinephrine but
not epinephrine release. Reserpine (sympatholytic), nadolol (β-adrenoceptor antagonist) or
right vagal nerve stimulation eliminated the late tachycardia, adrenalectomy, scopolamine
(central muscarinic antagonist) or hexamethonium did not. 4-AP increased TPVR, tran-
siently in WKY but sustained in SHR. Yohimbine (α2-adrenoceptor antagonist) prevented
the TPVR down-regulation in WKY. Reserpine and prazosin (α1-adrenoceptor antagonist)
eliminated the late vasoconstriction in SHR. Plasma epinephrine overﬂow increased in
nadolol-treated SHR. Through inhibition of KV, 4-AP activated parasympathetic ganglion
transmission and peripheral, neuronal norepinephrine release. The sympathetic compo-
nent dominated the 4-AP–HR-response in SHR. α2-adrenoceptor-dependent vasodilatation
opposed norepinephrine-induced α1-adrenergic vasoconstriction in WKY, but not SHR. A
βAR-activated, probably vagal afferent mechanism, hampered epinephrine secretion in
SHR. Thus, 4-AP activated the autonomic system and exposed mechanisms relevant to
hypertensive disease.
Keywords: total peripheral vascular resistance, heart rate, norepinephrine, epinephrine, parasympathetic nerves,
sympathetic nerves, adrenal, 4-aminopyridine
INTRODUCTION
The autonomic nervous system controls blood pressure (BP)
through its inﬂuence on theheart and vascular smoothmuscle cells
(VSMC). Sympathetic nerves, through β-adrenoceptors (AR), and
vagal, parasympathetic nerves, through muscarinic acetylcholine
(ACh) receptors (mAChR), are the main, acute, peripheral regula-
tors of heart rate (HR), with a positive and negative chronotropic
effect, respectively. VSMC tension is maintained by sympathetic
nerve activity, and opposed by endothelial relaxing factors such
as nitric oxide (NO). Although ACh is a potent stimulator of
NO synthesis in vitro, parasympathetic nerves do not innervate
the vascular endothelium. However, vagal nerve ACh release may
inﬂuence endothelial function through cholinergic inhibition of
inﬂammatory cell cytokine production (Borovikova et al., 2000).
In addition, ACh may inﬂuence norepinephrine release through
presynaptic receptors (Boehm and Kubista, 2002). Sympathetic
and parasympathetic control of BP exists in a homeostatic bal-
ance, integrated in the central nervous system (CNS) after afferent
signals from peripheral receptors, among them the baroreceptors.
The baroreﬂex has long been known to be impaired in hyperten-
sion (Thrasher, 2005). The disorder is regarded as an important
factor in the pathogenesis of the hypertensive disease,precipitating
an elevated resting BP,HR, and total peripheral vascular resistance
(TPVR; Esler et al., 2001; Palatini and Julius, 2009). A high resting
HR has been shown to be the most reliable predictor of cardiovas-
cular morbidity (Palatini and Julius, 1997; Tjugen et al., 2010).
The sympathetic system mostly elicits a positive response, such
as an increase in BP, HR, or vascular tension. These are easily
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measured. The function of the parasympathetic system is gener-
ally to hamper the adrenergic response. Parasympathetic inﬂu-
ence for instance on HR can therefore be recorded only through
its inhibitory effect on an adrenergically stimulated tachycardia.
Thus, identiﬁcation of pathogenic factors that cause a shift in the
autonomic control of cardiac functionor vascular tension, requires
an experimental condition where both the parasympathetic and
sympathetic components are active.
Active dual autonomic control is present in conscious indi-
viduals, and the parasympathetic/sympathetic balance can be
evaluated by studying autonomic reﬂexes, such as in baroreﬂex
sensitivity studies or respiratory mediated HR variability stud-
ies (Freeman, 2006). Such and similar studies make use of the
baroreceptor reﬂex, where an increase in BP will stimulate the
baroreceptors and increase parasympathetic inhibition of sympa-
thetic BP or HR control. Vice versa, a fall in BP reduces barore-
ceptor signaling, and sympathetic activity is increased due to
reduced parasympathetic inhibition. Such tests may not func-
tion in anesthetized animals, since anesthetics often disturb reﬂex
activation. In Nembutal-anesthetized rats, large changes in BP
elicited hardly any change in HR (Bjørnstad-Østensen and Berg,
1994; Berg et al., 2009). Still, anesthesia must be used in studies
where acute surgery is implemented in the experimental design.
However, the absence of reﬂexes may in fact be advantageous
since baroreﬂex activation will not interfere with the cardio-
vascular response to a pharmacologically stimulated transmitter
release.We knowof nomethod,whichwill simultaneously activate
both the parasympathetic and sympathetic nervous system in the
anesthetized rat.
The purpose of the present investigation was therefore to estab-
lish a method to achieve dual activation of both branches of
the autonomic nervous system in the anesthetized rat, so that
factors, which inﬂuence their balance, can be studied. We have
previously used 4-aminopyridine (4-AP) to study the role of
voltage-sensitive K+ channels (KV) in vascular tension control
(Berg, 2002). By inhibiting these channels, 4-AP induces depolar-
ization and opening of voltage-sensitive Ca2+ channels. InVSMC,
the entry of Ca2+ elicits vasoconstriction, while it in neurons
activates vesicular release of transmitters such as norepineph-
rine and ACh (Glover, 1982). Thus, apart from inducing VSMC
constriction in isolated aortic rings as well as in vivo, 4-AP also
induced a reserpine-sensitive tachycardia in both normotensive
(WKY) and spontaneously hypertensive rats (SHR; Berg, 2002,
2003). Furthermore, 4-AP-induced an atropine-sensitive saliva-
tion (Berg, 2002). It therefore seemed that 4-AP might activate
transmitter release from both branches of the autonomic nervous
system in the anesthetized rat. However, before 4-AP could be
used as a tool to analyze the altered autonomic control in hyper-
tension, the involvement of autonomic nerve transmitter release
in the cardiovascular response to 4-AP needed veriﬁcation. In
the present study, we tested if 4-AP indeed induced dual auto-
nomic nerve transmitter release, and if the impact of both the
parasympathetic and the sympathetic branch on the cardiovas-
cular system could be separated and identiﬁed. We also tested if
4-AP revealed changes in autonomic control of HR and TPVR
in SHR similar to that known to be present in hypertensive
disease.
MATERIALS AND METHODS
EXPERIMENTAL PROCEDURE
All experiments conformed to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes
of Health (NIH Publication No. 85-23, revised 1996), and were
approvedby the institutional ethics committee. The study included
130 male WKY (Wistar Kyoto, 284± 3 g) and 131 male SHR
(NHsd strain, 286± 2 g; 12–14 weeks) on conventional rat chow
diet (0.7% NaCl) and water ad lib. The rats were anesthetized
with Nembutal (70–75 mg/kg, i.p.), and connected to a positive-
pressure respirator, ventilated with air. Blood gas parameters were
maintained in both strains (Berg, 2002, 2003). Systolic (SBP)
and diastolic BP (DBP) were monitored through a catheter in
the femoral artery, and cardiac output (CO) and HR by a ﬂow-
probe on the ascending aorta (Berg et al., 2010). Mean arterial
BP [MBP= (SBP−DBP/3)+DBP] and TPVR (MBP/CO) were
calculated. Body temperature was monitored by a thermo sen-
sor inserted ingenually into the abdominal cavity, and kept at
37–38˚C by external heating. Drugs were dissolved in phosphate
buffered saline (PBS: 0.01 M Na-phosphate, pH 7.4, 0.14 M NaCl)
and administered through the femoral vein (0.6–1.0 ml/kg, bolus
injections) unless otherwise indicated (Table 1).
EXPERIMENTAL PROTOCOLS
Experimental details and function of drugs included in the exper-
iments are outlined in Table 1. All rats received an intravenous,
bolus injection containing a sub-maximal dose (Berg and Koteng,
1997) of the KV inhibitor 4-AP (34.5 μmol/kg, 1.3 ml/kg), and
were monitored for 25 min. Control rats were pre-treated with
PBS. To control 4-AP KV channel selectivity, the PBS-sham pre-
treatment was substituted with other K+ channel inhibitors, i.e.,
tetraethyl ammonium chloride (TEA, high conductance Ca2+-
activated K+ channels, BKCa, inhibitor) or glibenclamide (ATP-
sensitive K+ channels, KATP, inhibitor). To identify autonomic
nervous system components responsible for the cardiovascu-
lar response to 4-AP, rats were pre-treated with various auto-
nomic nervous system interventions. Involvement of ganglion
transmission in the response to 4-AP was investigated by pre-
treatment with the ganglion blocker hexamethonium. To iden-
tify the involvement of mAChR activation in the cardiovascu-
lar response to 4-AP, rats were pre-treated with atropine sulfate
or scopolamine hydrobromide, which have a central:peripheral
action of 1:10 and 1:1, respectively. Scopolamine would therefore
identify a role of CNS mACh-dependant sympathetic output, and
atropine predominantly an involvement of peripheral parasympa-
thetic nerve activation. The ability of the vagal nerve to inﬂuence
the cardiovascular response was veriﬁed by electrical stimulation
of the right vagal nerve, which primarily inﬂuences HR by inhibit-
ing sympathetic activation of the sinus node. The vagal nerve was
accessed through a cervical section, dissected free from the cer-
vical sympathetic chain and cut. The distal end of the nerve was
stimulated electrically using a suction electrode (2 ms duration,
7.5V, 10 Hz) from 5 min before injection of 4-AP to the end of
the 25-min 4-AP-observation-period. The role of activation of the
adrenergic system in the cardiovascular response to 4-APwas stud-
ied by pre-treatment with sympathetic nerve transmitter deple-
tion using reserpine, the αAR antagonists phentolamine, prazosin,
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Table 1 | Details on the drugs used for pre-treatment.
Drug used for pre-treatment Drug classification and purpose Dose (μmol/kg),
time before 4-AP
Reference for function or effective dose
TEA BKCa inhibitor, to test 4-AP KV selectivity 35 Berg and Koteng (1997)
Glibenclamide KATP inhibitor, to test 4-AP KV selectivity 40 Berg and Koteng (1997)
Hexamethonium chloride Peripheral nAChR antagonist, ganglion blockade 37 Wassermann (1971), Berg (2005)
Atropine sulfate Mainly peripheral mAChR antagonist 6.9, −20min Vargas and Ringdahl (1990), Berg (2002)
Scopolamine hydrobromide Mainly central mAChR antagonist 2.4, −30min Vargas and Ringdahl (1990), Berg (2002)
Reserpine Depletes sympathetic nerves of norepinephrine 2×8.2, i.p.,
−48+−24h
Berg (2002)
Phentolamine Non-selective αAR antagonist 6.3 Berg (2002, 2005)
Prazosin α1AR antagonist 0.24 Berg (2003, 2005)
Yohimbine α2AR antagonist 5 Berg (2003)
Nadolol Peripheral β1+2AR antagonist 8.5 Berg et al. (2010)
SR59230A β3AR antagonist 10, −5min Malinowska and Schlicker (1997), Berg et al. (2010)
Desipramine hydrochloride Inhibits norepinephrine reuptake 44, i.p., −4.5 h Miralles et al. (2002), Berg et al. (2009)
SR59230A was from Tocris Bioscience, Bristol, UK; the remaining drugs from Sigma Chemical Co., St. Louis, MO, USA. The drugs were administered i.v. as bolus
injections (0.6–1ml/kg) 10min prior to 4-AP, unless otherwise indicated.
and yohimbine, the βAR antagonists nadolol and SR59230A, or
bilateral adrenalectomy to identify an involvement of adrenal cat-
echolamine secretion (AdrX, performed 30 min before the ﬁrst
injection, (Berg, 2002, 2003; Berg et al., 2010). To augment the
effect of adrenergic stimulation, we inhibited norepinephrine
reuptake with desipramine. The number of rats per group is given
in Table 2.
PLASMA CATECHOLAMINES
In some of the experiments, 1.5 ml blood was sampled from the
femoral artery after the 25-min observation-period into tubes
containing 40μl 0.2 M glutathione with 0.2 M ethylene glycol-
bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA; 4˚C).
Plasma was stored at −80˚C, and the concentration of epinephrine
and norepinephrine determined using an HPLC-electrochemical
detection method as previously described (Jensen et al., 2005).
SALIVA MEASUREMENTS
Salivation is not present in anesthetized rats, but can be acti-
vated by parasympathetic or adrenergic stimulation; here by 4-AP.
Whole saliva was collected from the oral cavity with a pipette,
and saliva volume was determined by weight. The saliva was
stored at −20˚C. Salivary kallikrein, in the rat primarily a sub-
mandibular salivary gland component, which is stimulated pre-
dominantly by α-adrenoceptor activation (Ørstavik and Gautvik,
1977), was measured by S2266 amidolytic activity (Berg et al.,
1992).
STATISTICAL ANALYSES
Results are presented as mean values± SEM. The HR-response
to 4-AP are shown as real change, since ΔHR in response to 4-
AP will appear exaggerated when pre-treatment greatly reduced
baseline HR. The-TPVR-response is expressed in percent of base-
line to take into account that resistance∼1/r4, where r represents
resistance vessel radius. Recorded data were averaged every minute
throughout the experiment. During the initial response (1–2 min),
data were averaged every seventh heart beat to accurately deter-
mine HRnadir and TPVRmax. Signiﬁcant effects of pre-treatment
compared to that of PBS in the controls, i.e., from before pre-
treatment to before 4-AP, were determined by one-way ANOVA,
followed by two-sample Student’s t -tests. The 4-AP-response-
curves were evaluated with Repeated Measures Analyses of Vari-
ance and Covariance, ﬁrst as over-all tests, then for one or between
two group(s). One- and two-sample Student’s t -tests were used
to locate signiﬁcant responses and differences between groups,
respectively, at the initial response and after 25 min. The P-value
was for all tests and each step adjusted according to Bonfer-
roni, proceeding only when the presence of signiﬁcant responses
or differences was indicated. One-way ANOVA and two-sample
Student’s t -tests were used to evaluate differences in saliva vol-
ume, and saliva kallikrein and plasma catecholamine concentra-
tions (P≤ 0.05). In the presence of outliers, Kruskal Wallis tests
substituted the two-sample Student’s t -tests. Correlations were
determined with the Pearson Correlation test (P≤ 0.05).
RESULTS
THE RESPONSE TO 4-AP
The bolus injection of 4-AP-induced an immediate and sustained
increase in MBP in both strains (Figure 1). This response com-
prised an initial bradycardia in WKY with a subsequent, sustained
tachycardia in both strains, and a sustained increase in CO inWKY
(Figure 1). There was also an immediate rise in TPVR, which was
transient in WKY but sustained in SHR (Figure 1). 4-AP-induced
an increase in the plasma concentration of norepinephrine, which
was greater in SHR than in WKY (P < 0.001), but had no effect on
the concentration of epinephrine (Table 3). Since our purpose was
to study autonomic nerve activation and inﬂuence, we focused on
the changes elicited in HR and TPVR.
The HR- and TPVR-response to 4-AP was not signiﬁcantly
different after prior inhibition of BKCa channels with TEA or
KATP channels with glibenclamide (Figure 2), indicating that the
cardiovascular response to 4-AP selectively involved KV.
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Table 2 |The response to pre-treatment and the resulting MBP, HR, andTPVR after pre-treatment, i.e., baselines prior to 4-AP.
Pre-treatment WKY SHR
N ΔMBP
MBP after
(mm Hg)
ΔHR
HR after
(bpm)
ΔTPVR
TPVR after
(mmHg/ml/min)
N ΔMBP
MBP after
(mm Hg)
ΔHR
HR after
(bpm)
ΔTPVR
TPVR after
(mmHg/ml/min)
PBS 33 −1±1 −7±4 −0.2±0.1 33 −5±4 −11±3 −0.3±0.1
69±2 311±9 2.3±0.1 84±4** 343±9** 5.1±0.2***
TEA 6 −1±3 −34±4† −0.1±0.1 5 −38±16 −35±26 −2.2±0.6†
64±2 273±15† 2.3±0.1 89±12 348±16 4.2±0.7
Glybenclamide 6 7±3 −1±11 0.1±0.1 6 −3±10 −20±7 −0.4±0.3
71±4 311±21 2.5±0.3 100±10 336±10 5.8±0.5
Hexamethonium 8 −27±8† −23±10 −0.3±0.1 9 −36±9†† −51±13†† −1.6±0.5†
48±4††† 277±5† 2.0±0.1 45±3†† 302±14† 4.3±0.4†
Atropine 6 −4±3 −13±12 −0.4±0.13 6 −21±19 −41±19 −1.4±0.8
67±8 296±19† 2.5±0.3 71±6 338±9 5.2±0.3
Scopolamine Not done 6 −8±7 −39±9† −0.9±0.4
72±8 316±19 5.5±0.4
Right vagal n. stimulation 7 −9±5 −83±12††† −0.3±0.1 6 −12±10 −96±21†† −0.7±0.3
76±5 268±17†† 2.1±0.2 79±9 294±17† 5.3±0.4
AdrX+PBSa 6 −5±3 −14±3 −0.2±0.1 6 −1±2 −12±3 0.7±0.1††
62±6 316±27 2.4±0.1 77±4 324±21† 7.1±0.6†
Reserpine+PBSa 7 −2±1 −4±4 0.1±0.1 6 −1±2 −29±5 0.0±0.1
59±2† 275±21† 2.1±0.2 70±6 317±27 3.7±0.2††
Reserpine+ atropinea 6 −1±6 16±9 −1.0±0.6 6 −5±2 −16±6 −0.1±0.2
64±4 353±10 2.0±0.1 59±3 366±10 3.3±0.2†††
Nadolol 6 −3±2 −26±5† −0.2±0.0 6 −21±5 −75±10††† −0.6±0.3
68±3 361±11 2.4±0.3 70±7 331±10†† 4.9±0.3
Atropine+nadolol 6 0±2 −23±7 −0.2±0.1 6 −26±5 −85±6††† −1.5±0.3†
64±4 343±5 2.6±0.1 73±5 316±9††† 4.5±0.3
SR59230A 6 4±4 43±4††† −0.2±0.1 5 11±8 14±6 0.1±0.3
72±4 376±14† 2.3±0.1 100±2 407±6 5.2±0.3
Phentolamine 6 −12±1††† −55±4††† −0.3±0.1†† 6 −31±8† −24±9 −1.4±0.5
43±3††† 241±10†† 1.9±0.1†† 46±4†† 329±13††† 4.1±0.4
Prazosin 6 −9±3†† −21±8 −0.3±0.1† 5 −31±6† −35±14†† −0.9±0.2
61±4 296±9 2.4±0.3 52±5†† 351±20 5.4±0.5
Yohimbine 6 −22±5† −42±15 −0.9±0.1††† 6 −10±3 −6±5 −0.9±0.3
65±13 271±26 2.3±0.4 80±13 340±16 5.0±0.5
Desipramine+PBSa 7 −3±1 −3±11 0.0±0.0 6 2±3 15±7†† 0.5±0.2††
44±3††† 275±17 1.9±0.1 68±8 380±23 3.6±0.2†
aThe delta values indicate the response to injection of PBS or atropine during the experiment.The values after pre-treatment in these groups include the effect of AdrX,
reserpine, or desipramine. Comparisons were made between the WKY and SHR controls and between the PBS controls and corresponding experimental groups
(†). Values for the PBS+4-AP control groups represent pooled data from different sets of experiments. Statistical evaluation of differences due to pre-treatment
were done using the unpooled control group belonging to each set of experiments, consisting of at least six rats. N – number of rats per group. *,† – P≤0.05,
**,†† – P≤0.01, ***,††† – P≤0.001.
AUTONOMIC INVOLVEMENT IN THE INITIAL 4-AP-INDUCED
BRADYCARDIA, I.E., THE PARASYMPATHETIC COMPONENT
The 4-AP-induced, initial bradycardia in WKY was abolished by
the mAChR antagonist atropine (Figure 3) and hexamethonium
(Figure 4; P=NS one-sample Student’s t -tests, and P= 0.023
and 0.009, respectively, compared to the controls). AdrX, reser-
pine, nadolol, or SR59230A, did not inﬂuence the bradycar-
dia (Figure 5). These observations showed that 4-AP activated
ACh release and negative chronotropic mAChR, and that this
response also relied on nAChR, possibly within the ganglion. The
mAChR bradycardia was not further enhanced by electrical stim-
ulation of the right vagal nerve (Figure 3) or inﬂuenced by the
norepinephrine reuptake inhibitor desipramine (Figure 6).
In SHR, 4-AP-induced bradycardia only after pre-treatment
with reserpine or nadolol (P≤ 0.01), and this response was
abolished by additional pre-treatment with atropine (Figure 5).
Instead of bradycardia, 4-AP-induced an initial tachycardia in
hexamethonium- (Figure 4) and scopolamine-treated (Figure 7)
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SHR (P≤ 0.001). These results demonstrated that in SHR, 4-
AP activated a sympathetic nerve-dependent, β1/2AR-mediated
tachycardia, which shielded the initial parasympathetic response.
This initial balance was not altered by vagal nerve stimulation
(Figure 3).
Therewas no signiﬁcant correlation between the 4-AP-induced,
initial bradycardia, and the simultaneous increase in MBP within
each control group or within all groups in each strain.
AUTONOMIC INVOLVEMENT IN THE SUBSEQUENT 4-AP-INDUCED
TACHYCARDIA, I.E., THE SYMPATHETIC COMPONENT
The subsequent 4-AP-induced tachycardia was abolished as pre-
viously described (Berg, 2002, 2003) by reserpine in both strains
FIGURE 1 |The cardiovascular response to 4-AP inWKY and SHR. 4-AP
was injected as a bolus injection (arrow). The SBP- and DBP-responses
paralleled, MBP was therefore used to demonstrate the BP-response.
Curve evaluation was done by Repeated Measures Analyses of Variance
and Covariance with signiﬁcant responses located as described in Materials
and Methods, at HR nadir (brackets left of curves) and at 25min (brackets
right of curves). Please seeTable 2 for cardiovascular baselines prior to
4-AP. * – P<0.01.
(Figure 5). The tachycardia was also eliminated by the periph-
erally restricted β1+ 2AR antagonist nadolol, but was not signiﬁ-
cantly different after acuteAdrX or the β3AR antagonist SR59230A
(Figure 5). Like previously shown in WKY (Berg, 2002), the 4-AP-
induced adrenergic tachycardia in SHR was not different after the
centrally active mAChR antagonist scopolamine (Figure 7) or the
ganglion blocker hexamethonium (Figure 4). In SHR, the tachy-
cardia was delayed by desipramine (P≤ 0.003),which also allowed
a minor initial bradycardia (Figure 6).
Stimulation of the right vagal nerve abolished the 4-AP-
induced tachycardia in both strains,whereas atropine had no effect
(Figure 3). However, when the sympathetic component had been
eliminated by reserpine or nadolol, atropine increased the HR-
response to 4-AP in SHR (P≤ 0.014 and 0.006, respectively) but
not in WKY (Figure 5). These results demonstrated that in SHR,
4-AP-induced a sustained, parasympathetic mAChR activation,
the effect of which was totally shielded by the sympathetic nerve
response.
AUTONOMIC INVOLVEMENT IN THE 4-AP-INDUCED TPVR-RESPONSE
In agreement with previously published results (Berg, 2002, 2003),
the initial rise in TPVR in response to 4-AP was not reduced by
reserpine (Figure 8) or α1AR antagonist in either strain (P=NS;
Figure 9), compatible with vasoconstriction being due to inhibi-
tion of VSMC KV channels. In addition to our previous results,
we found that this vasoconstriction was not signiﬁcantly different
after SR59230A (Figure 8), hexamethonium (Figure 10), or vagal
nerve stimulation (Figure 11) in either strain, but was reduced
after reserpine+ atropine in SHR (Figure 8).
The subsequent down-regulation of TPVR in WKY was not
inﬂuenced by reserpine (Figure 8), phentolamine, or prazosin, but
was prevented by the α2AR antagonist yohimbine (Figure 9). The
return to TPVR baseline in this strain was also prevented in part
by the reuptake inhibitor desipramine (Figure 12). The sustained
late TPVR-response in SHR was due to neuronal norepinephrine
release and activation of a α1AR-mediated vasoconstriction since
it was eliminated by reserpine (Figure 8), phentolamine, and pra-
zosin but not by yohimbine (Figure 9). The late TPVR-response to
4-AP was not different after scopolamine in SHR (Figure 7), and
Table 3 |The effect of 4-AP on plasma catecholamine concentrations.
Treatment WKY SHR
Norepinephrine (nM) Epinephrine (nM) Norepinephrine (nM) Epinephrine (nM)
PBS+PBS (time-control) 0.5±0.1 8.1±1.5 1.2±0.2** 13.2±2.5
PBS+4-AP (control) 2.0±0.2††† 9.5±1.5 10.2±1.5***,††† 16.1±4.6
Scopolamine+4-AP 12.0±1.7 18.8±4.0
Right vagal n. stimulation+4-AP 4.2±0.7‡‡ 19.3±4.2‡ 11.2±1.6 44.1±14.1‡
Nadolol+4-AP 1.8±0.3 9.0±0.9 11.2±1.6 47.3±19.1‡‡
Atropine+nadolol+4-AP 2.6±0.4 13.6±2.5 12.3±1.5 43.1±7.1‡‡
SR59230A+4-AP 3.3±0.5 6.1±0.9 9.1±2.0 16.7±5.0
Comparisons were made between the WKY and SHR time-controls or 4-AP-controls, between the time-controls and PBS+4-AP-controls ( †), and between the
PBS+4-AP-controls and corresponding experimental groups ( ‡). Plasma from 12 rats were included in the PBS+4-AP control groups, and ﬁve to seven rats in the
other groups. *,‡ – P≤0.05, **,‡‡ – P≤0.01, ***,††† – P≤0.001.
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FIGURE 2 |The HR- andTPVR-response to 4-AP inWKY and SHR
after pre-treatment with other K+ channel inhibitors. Rats were
pre-treated with the BKCa inhibitor TEA or the KATP channel inhibitor
glibenclamide as indicated by symbol legend. Signiﬁcant responses
during the initial response and at 25min were subsequently located as
indicated (* within symbol). Signiﬁcant group differences were not
detected. The effects of TEA and glibenclamide on baselines are shown
inTable 2. * – P≤0.025.
FIGURE 3 |The HR-response to 4-AP after pre-treatment with the
mAChR antagonist atropine or electrical stimulation of the right,
efferent vagal nerve. After curve evaluation, signiﬁcant responses (* within
symbol) and group differences at HR nadir (brackets left of curves) and at
25min (brackets right of curves) were located as indicated. Atropine had
little effect on the HR baseline, whereas vagal stimulation greatly reduced
HR in both strains (Table 2). * – P<0.025.
in both strains not altered by hexamethonium (Figure 10), vagal
nerve stimulation, atropine, alone (Figure 11) or combined with
nadolol, nadolol alone, AdrX, or SR59230A (Figure 8).
AUTONOMIC INVOLVEMENT IN THE 4-AP-INDUCED CHANGES IN
PLASMA CATECHOLAMINE CONCENTRATIONS
Norepinephrine and epinephrine overﬂow to plasma in 4-
AP-treated WKY was increased by vagal nerve stimulation
(Table 3). In SHR, we detected no differences in the plasma
FIGURE 4 |The HR-response to 4-AP after pre-treatment with nAChR
antagonist, i.e., the ganglion blocker hexamethonium. Signiﬁcant
responses (* within symbol) and group differences at the initial HRnadir
(brackets left of curves) and after 25min (none detected) were as indicated.
Hexamethonium reduced baseline HR in both strains (Table 2).
* – P≤0.025.
concentration of norepinephrine, but the concentration of epi-
nephrine was increased after vagal nerve stimulation, nadolol,
and atropine+ nadolol, but not after scopolamine or SR59230A
(Table 3).
4-AP-INDUCED SALIVATION
4-AP activated salivary secretion with a greater efﬁcacy in WKY
than in SHR (40± 8 and 13± 4μl whole saliva, respectively,
P= 0.003), starting 4–6 min after the injection of 4-AP. Sali-
vary kallikrein (S2266-activity) concentration and total secretion
were higher in SHR (348± 82 U/ml and 15.6± 5.7 U, respec-
tively) than in WKY (112± 35 U/ml and 3.4± 0.2 U; P≤ 0.009).
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FIGURE 5 | HR-response to 4-AP after removal of components of the
adrenergic system.The rats were pre-treated to eliminate adrenal (AdrX) or
neuronal (reserpine) catecholamines, peripheral β1+2AR (peripherally
restricted antagonist nadolol), or β3AR-activity (β3AR antagonist SR59230A).
Reserpine and nadolol were also combined with mAChR antagonist
(atropine), as indicated by symbol legends. Column graphs to the right
shows HRnadir during the initial response (1–2min) and ΔHR at 25min.
Signiﬁcant responses (* within column) and group differences (brackets)
were located as indicated. Baseline HR was slightly reduced after reserpine
and nadolol inWKY and clearly after nadolol in SHR (Table 2). * – P≤0.025.
FIGURE 6 |The effect of the norepinephrine reuptake inhibitor
desipramine on the HR-response to 4-AP. Signiﬁcant responses (* within
symbol) at HR nadir and at 25min were located as indicated. A difference
between the SHR control and the desipramine-treated group was detected
at 10min (* between curves). Baseline HR was not different after
desipramine (Table 2). * – P≤0.025 and 0.0167 for signiﬁcant responses
and group differences, respectively.
4-AP-induced salivation was absent in all groups pre-treated with
atropine, scopolamine, or hexamethonium, but was not much
inﬂuenced by other pre-treatments (data not shown).
FIGURE 7 |The effect of scopolamine on the HR- (A) andTPVR- (B)
response to 4-AP in SHR. Scopolamine had no effect on the
MBP-response to 4-AP (not shown).We have previously shown that
scopolamine did not signiﬁcantly alter the response inWKY (Berg, 2002).
Signiﬁcant responses (* within symbol) during the initial response and after
25min, as well as group differences at these times (brackets) were
detected as indicated. Scopolamine caused a minor reduction in baseline
HR (Table 2). * – P≤0.025.
DISCUSSION
The present results demonstrated that 4-AP activated both the
sympathetic and the parasympathetic branch of the autonomic
nervous system in anesthetized rats. The HR-response elicited
by 4-AP, substituted an initial parasympathetic bradycardia fol-
lowed by a sympathetic tachycardia. The HR-response in SHR
reﬂected the shifted autonomic control of HR in hypertension,
i.e., sympathetic hyperactivity with low parasympathetic inﬂu-
ence, in spite of that parasympathetic activation was actually
greater in SHR than in WKY. Norepinephrine release, elicited by
4-AP, elevated TPVR in SHR but not WKY, due to the absence of
an α2AR vasodilatory component, which down-regulated tension
in WKY. We also detected a βAR-mediated inhibition of adrenal
epinephrine secretion in SHR.
The 4-AP-induced parasympathetic activation was demon-
strated through the ability of the mAChR antagonist atropine
to eliminate the initial 4-AP-induced bradycardia in WKY. In
addition, 4-AP activated salivary secretion, which was blocked
by pre-treatment with atropine. The initial bradycardia was also
prevented by the nAChR antagonist, ganglion blocker hexam-
ethonium, suggesting a baroreﬂex activation. However, there was
no correlation between the initial ΔMBP and ΔHR, and, under
similar conditions, a rise in BP due to selective stimulation of
sympathetic nerve norepinephrine release by tyramine, elicited
tachycardia only (Berg et al., 2010). Moreover, hexamethonium
also abolished the atropine-sensitive salivation, which is not part
of the baroreﬂex. We therefore concluded that 4-AP activated
presynaptic ACh release and, through that, postsynaptic nAChR
in parasympathetic ganglions, parallel to that observed in isolated
rabbit superior cervical ganglions (Simmons andDun,1984). Sub-
sequent release of ACh from the postsynaptic parasympathetic
neuronwas responsible for activationof themAChR,which caused
the initial bradycardia.
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FIGURE 8 |TheTPVR- (A) and MBP- (B) response to 4-AP after blockade
of components of the adrenergic system. Adrenal catecholamines were
eliminated by AdrX, neuronal norepinephrine by reserpine, β1+2AR activity
with the peripherally restricted antagonist nadolol, and β3AR-activity with
the β3AR antagonist SR59230A. Reserpine and nadolol were given alone or
combined with mAChR antagonist (atropine), as indicated by symbol
legends. Signiﬁcant responses (* within symbol) and group differences
(brackets) were located as indicated. Baseline TPVR was higher in AdrX
SHR, and reduced after reserpine, reserpine+ atropine, and
nadolol+ atropine in SHR. MBP was lower after reserpine inWKY (Table 2).
* – P≤0.025.
The tachycardia, which followed the initial bradycardia, was
caused in both strains by 4-AP-activated norepinephrine release.
This conclusion was based on the fact that reserpine, like pre-
viously described (Berg, 2002, 2003), but not AdrX, eliminated
this response. The same was true for the late rise in TPVR in
SHR. The tachycardia was also eliminated by the peripherally
restrictedβ1+ 2ARantagonist nadolol, and the lateTPVR-response
in SHR also by the α1AR antagonist prazosin. In addition, 4-AP
increased the plasma concentration of norepinephrine but not
epinephrine. 4-AP evidently crossed the blood brain barrier, evi-
denced by the occurrence of muscular twitches due to cortical
stimulation (Paskov et al., 1986). However, scopolamine and hexa-
methonium did not alter the 4-AP-induced tachycardia or the late
TPVR-response. Thus, these 4-AP-induced adrenergic responses
didnot rely onCNSACh release and increased sympathetic output,
or on ganglion transmission. We therefore concluded that 4-AP
activated release of norepinephrine from peripheral sympathetic
nerve terminals.
In WKY, the parasympathetic and sympathetic activation was
separated in time, since the initial bradycardia was not inﬂuenced
by reserpine or nadolol and the subsequent tachycardia was not
altered by atropine, even in the presence of sympatho-inhibition
FIGURE 9 |TheTPVR- (A), MBP- (B), and HR- (C) response to 4-AP in
WKY and SHR after pre-treatment with αAR antagonists. Signiﬁcant
responses (* within symbol) and group differences during the immediate
TPVRmax and at 25min (brackets) were located as indicated. All antagonists
reduced baseline TPVR inWKY, but not signiﬁcantly in SHR (Table 2).
Baseline MBP was lower after all three antagonists inWKY and after
phentolamine and prazosin in SHR. Baseline HR was lower after
phentolamine inWKY and after phentolamine and prazosin in SHR (Table 2).
* – P≤0.025.
with reserpine or nadolol. In SHR, the sympathetic nerve-
dependent, positive chronotropic response totally dominated the
HR-response to 4-AP, in spite of that ACh release did occur
even throughout the 4-AP-observation-period. This conclusion
was made because an initial, atropine-sensitive bradycardia was
observed in SHR only after pre-treatment with the sympatholyt-
ics reserpine or nadolol, and after such pre-treatment, atropine
increased also the late HR-response to 4-AP in this strain. Fur-
thermore, after inhibition of the parasympathetic componentwith
hexamethonium or scopolamine, 4-AP-induced an initial tachy-
cardia in SHR. The functionality of vagal mAChR inhibition of
sympathetic nerve-induced stimulation of the sinus node was also
veriﬁed by that the 4-AP-induced tachycardia was eliminated by
electrical stimulation of the right vagal nerve in SHR, as in WKY.
The HR-response to 4-AP in SHR therefore fully reﬂected the
shifted autonomic balance in hypertension, with a sympathetic
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FIGURE 10 |TheTPVR- (A) and MBP- (B) response to 4-AP after
pre-treatment with the peripherally restricted nAChR antagonist,
ganglion blocker hexamethonium. Signiﬁcant responses (* within
symbol) during the initial response and after 25min, were detected as
indicated. Signiﬁcant group differences were not detected.
Hexamethonium reduced baseline MBP in both strains and also TPVR in
SHR (Table 2). * – P≤0.025.
component dominating over parasympathetic HR control (Pala-
tini and Julius, 2009; Tjugen et al., 2010), in spite of an augmented
parasympathetic activation in SHR.
A sympathetic dominance was also detected for the 4-AP-
induced salivation. Saliva ﬂow, a 4-AP-induced parasympathetic
response since it was inhibited by atropine, was lower in SHR than
in WKY. In addition, the saliva concentration and total secretion
of kallikrein, in the rat primarily an αAR-activated salivary com-
ponent (Ørstavik and Gautvik, 1977), was higher in SHR than in
WKY.
An initial bradycardia and a delayed development of the tachy-
cardia were seen in desipramine-treated SHR. This observation
suggested that increased βAR activation hampered the positive
chronotropic response to norepinephrine release, in agreement
with that excessive signaling may hamper cardiac function (Noor
et al., 2010). A negative chronotropic effect due to β3AR-activity
did not inﬂuence the HR-response to 4-AP in either strain,
although the β3AR antagonist SR59230A, as in previous studies
(Berg et al., 2010), increased resting HR in WKY but not SHR.
In addition to inhibiting VSMC and autonomic nerve KV, 4-
AP also inhibits K+ channels mediating cardiac repolarization
currents, such as the transient outward current and the delayed
rectiﬁer currents (Ridley et al., 2003; Tamargo et al., 2004). Inhi-
bition of these currents results in action potential prolongation,
which, in the absence of other signiﬁcant electrophysiological
FIGURE 11 |TheTPVR- (A) and MBP- (B) response to 4-AP after atropine
and vagal nerve stimulation. Signiﬁcant responses (* within symbols) at
the initial peak response and after 25min were detected as indicated.
Signiﬁcant group differences were not detected. Atropine and vagal nerve
stimulation did not alter MBP andTPVR baselines (Table 2). * – P≤0.025.
changes, is a hallmark of failing ventricular myocardium and also
produces arrhythmias (Tomaselli and Marban, 1999). Studies on
the HR-response to 4-AP may therefore be of particular interest
for understanding mechanisms responsible for arrhythmia and
cardiac events in hypertensive disease.
Also the 4-AP-induced rise in TPVR was mediated through
peripheral actions, ﬁrst, in both strains, by inhibition of VSMC
KV (Berg, 2002, 2003), and subsequently, in SHR, through acti-
vation of peripheral neuronal norepinephrine release. This was
concluded since scopolamine and the ganglion blocker hexam-
ethonium did not inﬂuence the immediate or the late TPVR-
response to 4-AP. In addition, reserpinedidnot inﬂuence the initial
but hampered the late TPVR-response in SHR. Still, there was a
decrease in the initial TPVR-response in SHR pre-treated with
reserpine+ atropine, suggesting that the VSMC KV activity relied
on ACh and mAChR. In isolated aortic rings, the 4-AP-induced
vasoconstriction was sustained (Berg, 2002, 2003), whereas a
down-regulation of tension was observed in WKY in vivo. This
down-regulation in WKY involved an α2AR vasodilatory compo-
nent since the non-selectiveα2ARantagonist yohimbine prevented
the return to baseline. This elevated late TPVR-response in WKY
after α2AR inhibition, represented a α1AR-mediated vasoconstric-
tion, since TPVRwas down-regulated after theα1+ 2AR antagonist
phentolamine. The α2AR vasodilatory component opposing the
α1AR vasoconstriction inWKYmay possibly represent endothelial
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FIGURE 12 |TheTPVR- (A) and MBP- (B) response to 4-AP after
inhibition of norepinephrine reuptake with desipramine. Signiﬁcant
responses (* within symbol) and group differences during the immediate
TPVRmax (none detected) and after 25min (brackets right of curve) were
located as indicated. Desipramine reduced baseline TPVR in both strains
and also MBP inWKY (Table 2). * – P≤0.025.
α2AR, which may activate nitric oxide synthesis (NO; Shafaroudi
et al., 2005).When shifting this balance by augmenting the sympa-
thetic component by desipramine, α2AR-mediated vasodilatation
failed to fully down-regulate TPVR also in WKY.
We previously observed that down-regulation of TPVR in
response to tyramine-stimulated, selective norepinephrine release,
depended in SHR exclusively on adrenal catecholamine(s) and
activation of β2+ 3AR-mediated vasodilatation, with no inﬂuence
of the nerve-dependent activation of postsynaptic β1AR, which
down-regulated tension in WKY (Berg et al., 2010). Since AdrX,
nadolol, and SR59230A did not inﬂuence the late TPVR-response
to 4-AP in either strain, 4-AP apparently blocked βAR-mediated
vasodilatation. This conclusionwas supported by that 4-AP halved
the fall in TPVR in response to the βAR agonist isoprenaline (data
not shown). Therefore, when βAR-mediated vasodilatation was
prevented by 4-AP, α2AR-mediated vasodilatation was revealed,
but inWKYonly, in agreementwith thepresenceof α2ARdisorders
in SHR (Feres et al., 1998; Zugck et al., 2003).
Although 4-AP itself did not inﬂuence the plasma epinephrine
concentration, efferent vagal stimulation increased circulating epi-
nephrine in both strains, demonstrating a positive vagal inﬂuence
on adrenal epinephrine secretion. In SHR, plasma epinephrine
also increased after pre-treatment with nadolol, alone or com-
binedwith atropine, but not SR59230A, andwithout simultaneous
changes in norepinephrine overﬂow. The latter observation was
likely to be explained by a negative feedback loop, where adrenal
catecholamine(s) activated β1/2AR on vagal, afferent nerves,which
through a CNS relay has been shown to hamper adrenal cate-
cholamine secretion (Mravec, 2011). This mechanism apparently
involved 4-AP-induced ACh release, since nadolol did not alter
plasma epinephrine concentration in SHR infused with tyramine
(Berg, unpublished observations). This feedback mechanism was
not detected in WKY, possibly due to a lower sympathetic tone
in this strain, although an elevated norepinephrine overﬂow to
plasma was observed in vagal-stimulatedWKY. This latter increase
may result from activation of presynaptic release-stimulating
mAChR (Boehm and Kubista, 2002).
CONCLUSION
4-AP activated both branches of the autonomic nervous system,
and their inﬂuence on the cardiovascular system could be sepa-
rated and identiﬁed. In SHR, a sympathetic nerve-dependent nor-
epinephrine release dominated and prevented parasympathetic
inﬂuence on HR, even though the parasympathetic component
actually was augmented in SHR. In addition, in the presence of 4-
AP, norepinephrine release activated an α2AR-mediated vasodila-
tory component,which opposed andprevented anα1AR-mediated
increase in TPVR in WKY. This α2AR-mediated vasodilatory
mechanism was not functional in SHR. We also detected a β1/2AR-
dependent inhibition of adrenal catecholamine release in SHR,
possibly due to activation of a negative feedbackmechanismmedi-
ated by β1/2AR on afferent vagal ﬁbers. 4-AP therefore exposed
mechanisms involved in autonomic nervous system disorders in
SHR, and may allow identiﬁcation of factors responsible for these
important changes in hypertension.
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